VLS Valneva SE

VALNEVA Declaration of shares and voting rights: December 31, 2024

VALNEVA Declaration of shares and voting rights: December 31, 2024

VALNEVA

Declaration of shares and voting rights

December 31, 2024

__________________________________________________________________________________________

Company name: VALNEVA

Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)

Regulated market of Euronext Paris - Compartment B

Declaration date: January 3, 2025

Number of shares

composing the share capital of Valneva
Total number of voting rights including suspended voting rights*Description of the change Date on which this change was recognizedTotal number of voting rights excluding suspended voting rights**






162,521,524









ordinary shares with a par value of €0.15 each
178,404,975





Transfer into bearer form of 300 shares with double voting rights









Sale of 150 shares with double voting rights









Definitive attribution of 27,521 free ordinary shares









Double voting rights granted on 6,177 ordinary shares





December 2, 2024









December 5, 2024









December 6, 2024









Between December 1 & 28, 2024
178,280,653

___________________________

* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

** Net (or exercisable at a General Meeting) voting rights.

Attachment



EN
03/01/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Valneva SE

 PRESS RELEASE

Valneva to Meet with Investors during the J.P. Morgan Healthcare Confe...

Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference Saint Herblain (France), January 6, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces that members of its management team will meet one-on-one with existing shareholders and hold meetings with other institutional specialist investors during the 43nd Annual J.P. Morgan Healthcare Conference, January 13-15, 2025 in San Francisco. Valneva’s CEO Thomas Lingelbach and CFO Peter Bühler will discuss the Company’s commercial portfolio of vaccines, which is expected to generate €160 -...

 PRESS RELEASE

VALNEVA Declaration of shares and voting rights: December 31, 2024

VALNEVA Declaration of shares and voting rights: December 31, 2024 VALNEVA Declaration of shares and voting rights December 31, 2024__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: January 3, 2025 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the change Date on which this change was recognizedTotal num...

Bruno Bulic
  • Bruno Bulic

Valneva pushing Ixchiq in Asia

Valneva announced an exclusive license agreement with India-based Serum Institute of India (SII), for the supply of the Chikungunya vaccine Ixchiq in Asia, a partnering falling under the scope of the Coalition for Epidemic Preparedness Innovations (CEPI) for low-and-middle-income countries (LMICs)

 PRESS RELEASE

Valneva Successfully Expands Access to Asia for its Chikungunya Vaccin...

Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India Saint-Herblain (France), Pune, (India), December 19, 2024 – (“Valneva” or “the Company”), a specialty vaccine company, and Serum Institute of India (SII), the world’s largest manufacturer of vaccines by number of doses, today announced an exclusive license agreement for Valneva’s single-shot chikungunya vaccine that enables supply of the vaccine in Asia. The collaboration to support broader access to the vaccine in low-and-middle-income countries (LMICs) in the region falls within the fram...

 PRESS RELEASE

Valneva accroît l’accessibilité de son vaccin contre le chikungunya en...

Valneva accroît l’accessibilité de son vaccin contre le chikungunya en Asie grâce à une collaboration avec le Serum Institute of India Saint-Herblain (France), Pune, (Inde), le 19 décembre 2024 – (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, et le Serum Institute of India (SII), plus grand fabricant de vaccins au monde en nombre de doses, ont annoncé la signature d’un accord de licence exclusif pour le vaccin à dose unique de Valneva contre le chikungunya, permettant la fourniture du vaccin en Asie. Cette collaboration destinée à accroître l’accessibilité du...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch